AI-ACCELERATED DRUG DISCOVERY
Available from Reaxense
This protein is integrated into the Receptor.AI ecosystem as a prospective target with high therapeutic potential. We performed a comprehensive characterization of Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit gamma isoform including:
1. LLM-powered literature research
Our custom-tailored LLM extracted and formalized all relevant information about the protein from a large set of structured and unstructured data sources and stored it in the form of a Knowledge Graph. This comprehensive analysis allowed us to gain insight into Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit gamma isoform therapeutic significance, existing small molecule ligands, relevant off-targets, and protein-protein interactions.
Fig. 1. Preliminary target research workflow
2. AI-Driven Conformational Ensemble Generation
Starting from the initial protein structure, we employed advanced AI algorithms to predict alternative functional states of Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit gamma isoform, including large-scale conformational changes along "soft" collective coordinates. Through molecular simulations with AI-enhanced sampling and trajectory clustering, we explored the broad conformational space of the protein and identified its representative structures. Utilizing diffusion-based AI models and active learning AutoML, we generated a statistically robust ensemble of equilibrium protein conformations that capture the receptor's full dynamic behavior, providing a robust foundation for accurate structure-based drug design.
Fig. 2. AI-powered molecular dynamics simulations workflow
3. Binding pockets identification and characterization
We employed the AI-based pocket prediction module to discover orthosteric, allosteric, hidden, and cryptic binding pockets on the protein’s surface. Our technique integrates the LLM-driven literature search and structure-aware ensemble-based pocket detection algorithm that utilizes previously established protein dynamics. Tentative pockets are then subject to AI scoring and ranking with simultaneous detection of false positives. In the final step, the AI model assesses the druggability of each pocket enabling a comprehensive selection of the most promising pockets for further targeting.
Fig. 3. AI-based binding pocket detection workflow
4. AI-Powered Virtual Screening
Our ecosystem is equipped to perform AI-driven virtual screening on Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit gamma isoform. With access to a vast chemical space and cutting-edge AI docking algorithms, we can rapidly and reliably predict the most promising, novel, diverse, potent, and safe small molecule ligands of Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit gamma isoform. This approach allows us to achieve an excellent hit rate and to identify compounds ready for advanced lead discovery and optimization.
Fig. 4. The screening workflow of Receptor.AI
Receptor.AI, in partnership with Reaxense, developed a next-generation technology for on-demand focused library design to enable extensive target exploration.
The focused library for Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit gamma isoform includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit gamma isoform
partner:
Reaxense
upacc:
Q13362
UPID:
2A5G_HUMAN
Alternative names:
PP2A B subunit isoform B'-gamma; PP2A B subunit isoform B56-gamma; PP2A B subunit isoform PR61-gamma; PP2A B subunit isoform R5-gamma; Renal carcinoma antigen NY-REN-29
Alternative UPACC:
Q13362; B4DYJ8; B5BUA5; F5GWP3; Q14391; Q15060; Q15174; Q6ZN33
Background:
The Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit gamma isoform, known by alternative names such as PP2A B subunit isoform B'-gamma and Renal carcinoma antigen NY-REN-29, plays a pivotal role in cellular processes. It modulates substrate selectivity and catalytic activity, directing the localization of the catalytic enzyme to specific subcellular compartments. The PP2A-PPP2R5C holoenzyme is crucial for dephosphorylating and activating TP53, thereby playing a role in DNA damage-induced inhibition of cell proliferation and regulating the ERK signaling pathway through ERK dephosphorylation.
Therapeutic significance:
Understanding the role of Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit gamma isoform could open doors to potential therapeutic strategies.
